This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
bioMérieux, Inc.
bioMérieux, Inc., a leading global player in the field of in vitro diagnostics, is headquartered in the United States and operates extensively across North America and beyond. Founded in 1963, the company has established itself as a pioneer in microbiology and immunoassays, providing innovative solutions that enhance patient care and public health. With a diverse portfolio of products and services, bioMérieux focuses on areas such as infectious disease diagnostics, industrial microbiology, and molecular biology. Their unique offerings, including rapid diagnostic tests and automated systems, set them apart in the competitive landscape. Recognised for their commitment to quality and innovation, bioMérieux has achieved significant milestones, solidifying their market position as a trusted partner in healthcare and laboratory settings worldwide.
DitchCarbon Score
How does bioMérieux, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
bioMérieux, Inc.'s score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
bioMérieux, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of bioMérieux S.A., which cascades its emissions data and climate commitments down to its subsidiaries. As of now, bioMérieux, Inc. has not outlined any specific reduction targets or initiatives in its own reporting. However, it is important to note that the climate commitments and performance metrics are inherited from bioMérieux S.A. at the first cascade level. This includes participation in initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), which are aimed at reducing greenhouse gas emissions and enhancing transparency in climate-related performance. While specific emissions figures are not provided, bioMérieux, Inc. is part of a broader corporate strategy focused on sustainability and climate action, reflecting the industry's increasing emphasis on reducing carbon footprints and addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 31,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 241,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
bioMérieux, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
